Expanding Sales of Generic Pharmaceutical Ingredients and New Materials Through Customer Proposals

「In the pharmaceutical raw materials platform division, new deliveries of imported active pharmaceutical ingredients and expansion of existing products led to strong sales and profit, although the cost ratio deteriorated for some products.」

「In the pharmaceutical raw materials platform division, the trading business focused on sales of high-value-added imported active pharmaceutical ingredients that are less susceptible to price competition and pharmaceutical intermediates for new drugs. Domestic B&S (Buy-Sell), which provides a stable earnings base, grew as planned.」

「In the pharmaceutical raw materials division, manufacturing and sales of products remained strong, supported by the effects of price revisions and a significant contribution from contract manufacturing projects. In trading sales of imported products and other merchandise, we focused on raw materials for generic drugs and intermediates for new drugs, and sales were at the same level as in the prior-year period.」

「In the pharmaceutical raw materials division, we focused on sales of raw materials for generic drugs and intermediates for new drugs in the trading business involving imported products and other merchandise, with both sales volume and sales prices remaining firm. In manufacturing and sales of products, sales also remained strong, and price revisions and other factors led to an improvement in the profit margin.」

「At スペラネクサス株式会社 in the pharmaceutical raw materials division, the trading function focused on sales of raw materials for generic drugs and intermediates for new drug manufacturers, with both sales volume and sales prices improving year on year, resulting in strong sales. In the manufacturing function, we focused on developing the high-potency active pharmaceutical ingredient manufacturing facility and securing contract manufacturing projects, achieving a certain degree of success, although sales volume for some in-house manufactured products declined.」

「At スペラネクサス株式会社 in the pharmaceutical raw materials division, the trading function focused on sales of raw materials for generic drugs and intermediates for new drug manufacturers, while the manufacturing function focused on securing additional contract manufacturing projects for the newly operational high-potency active pharmaceutical ingredient manufacturing facility. As a result, sales remained strong because sales of raw materials for newly developed generic products and new projects for new drug manufacturers exceeded the prior-year level.」

「In the trading function of the pharmaceutical raw materials division, we focused on sales of raw materials for generic drugs and intermediates for new drugs, while in the manufacturing function, we focused on securing contract manufacturing projects. As a result, sales remained strong because sales of raw materials for newly developed generic products and new projects for new drug manufacturers exceeded the prior-year level.」

「In the trading function of the pharmaceutical raw materials division, we focused on sales of new raw materials for generic drugs and intermediates for new drugs, while in the manufacturing function, we focused on securing new contract manufacturing projects. As a result, sales remained strong.」

「On the sales side, we focused on new sales of generic active pharmaceutical ingredients and intermediates for new drugs. On the manufacturing side, we focused on securing and executing new contract manufacturing projects.」

「The pharmaceutical raw materials field remained generally firm, supported by sales contributions from new imported generic products and intermediates, increased demand resulting from quality problems in the market, and strong performance by new contract-manufactured in-house products.」

「Under these conditions, in the pharmaceutical raw materials sales field, we strengthened sales capabilities by securing new products, mainly generic drugs, and expanding sales of chemicals, while in the pharmaceutical raw materials manufacturing field, we focused on securing new contract manufacturing opportunities for intermediates and clinical trial drugs.」

「In the pharmaceutical raw materials field, amid the lack of an expected recovery in demand due to the impact of COVID-19, we focused on responding to higher raw material costs through pricing, delivering new imported generic active pharmaceutical ingredients and intermediates, and expanding sales of in-house products.」

「In the pharmaceutical raw materials sales field, we worked to secure new products, mainly generic drugs. In the pharmaceutical raw materials manufacturing field, we focused on securing new contract manufacturing opportunities for intermediates and clinical trial drugs. In the CDMO field, we expanded the service area through the integration of JITSUBO株式会社 into the Group, strengthened sales functions within the Group, and worked to secure repeat projects from major customers and develop new customers.」

「Under these conditions, in the pharmaceutical raw materials sales field, we worked to strengthen sales capabilities by securing new products, mainly generic drugs, and expanding sales of chemicals. In the pharmaceutical raw materials manufacturing field, we focused on securing new contract manufacturing opportunities for intermediates and clinical trial drugs. In the CDMO field, we strengthened coordination among the Group’s sales functions and worked to secure repeat projects, mainly from major customers.」

「In the fine chemicals business, in the pharmaceutical raw materials sales field, we worked to strengthen sales capabilities by securing new products, mainly generic drugs, and expanding sales of chemicals. In manufacturing, we focused on securing new contract manufacturing opportunities for intermediates and clinical trial drugs.」

「On the sales side, we focused on strengthening sales of generic active pharmaceutical ingredients and new pharmaceutical intermediates, treated the medium-molecule pharmaceutical field as a priority market, and developed proposals for overseas products and new raw materials. On the manufacturing side, we promoted discontinuation of manufacturing and sales and price revisions to improve profitability.」

「In the pharmaceutical raw materials field, we strengthened sales of generic active pharmaceutical ingredients and intermediates for new drugs, promoted stable supply of raw materials through multiple sourcing, and strengthened efforts to secure new development opportunities involving pharmaceutical intermediates, cosmetic ingredients and clinical trial drug intermediates.」

「On the sales side, we focused on strengthening sales of generic active pharmaceutical ingredients and intermediates for new drugs, while treating the medium-molecule pharmaceutical field as a priority market for both sales and manufacturing and developing proposals for overseas products and new raw materials. On the manufacturing side, we promoted stable supply of raw materials through multiple sourcing.」

「In the fine chemicals business, amid delays and difficulties in procuring overseas raw materials due to the spread of COVID-19, we pursued multiple sourcing of raw materials to meet firm demand for pharmaceutical raw materials. We also worked to improve profitability through process improvements and price adjustments for existing products, and to develop new products in the medium-molecule pharmaceutical field.」

「We pursued multiple sourcing of raw materials to address procurement difficulties, higher costs and firm demand resulting from accidents at Chinese chemical manufacturers and other factors. At the same time, under pressure from higher raw material and logistics costs, we worked to improve profitability by adjusting sales prices for existing products. As a result, manufacturing and sales of pharmaceutical raw materials remained firm for antiallergic drug products and ulcerative colitis drugs, and sales price adjustments gradually progressed. In addition, strong performance in contract-manufactured electronic and functional materials led to significant growth in both sales and operating profit.」

「In the pharmaceutical raw materials field, amid difficulty securing profits due to stockpiling ahead of drug price revisions associated with the consumption tax increase and requests for price reductions, we worked on proposals for drug discovery intermediates and medium-molecule drugs and stable supply through multiple sourcing. Although rising costs reduced profit, the start of transactions for new medium-molecule drugs, adoption of newly developed generic products, firm sales of existing pharmaceutical raw materials and higher sales of fine chemical contract-manufactured products contributed to results, with sales and profit both increasing significantly overall.」

「Under these conditions, in the pharmaceutical raw materials field, we focused on multiple sourcing of intermediates for raw material manufacturers, proposals for raw materials from countries other than China, and proposals for key intermediates and solvents to new drug manufacturers, based on stable supply. In new fields, we began initiatives in nucleic acid drug and amino acid-related pharmaceutical intermediates. Although some raw materials from China became difficult to obtain, we worked to stabilize supply by proposing alternative raw materials, and manufacturing and sales of existing pharmaceutical raw materials remained firm. Raw materials for ulcerative colitis and cerebral thrombosis treatments also performed well, resulting in growth in both sales and operating profit.」

「In the pharmaceutical raw materials field, while higher logistics costs, cost increases associated with China’s environmental regulations and procurement difficulties became evident, manufacturers and distributors continued to press strongly for price reductions, making it difficult to secure profits. We therefore pursued multiple sourcing of raw materials, sales price adjustments, and proposals for pharmaceutical raw materials including new pharmaceutical intermediates, excipients and the medium-molecule field. Although higher raw material prices pushed up costs, active pharmaceutical ingredients for gastrointestinal drugs and cerebral thrombosis grew significantly as new raw materials, while in-house manufactured antiallergic drugs and contract-manufactured electronic and functional materials also contributed, resulting in strong sales and profit.」

「Under these conditions, in the pharmaceutical raw materials field, we worked closely with generic drug manufacturers to actively develop generic raw materials using proprietary processes and propose raw materials for new and existing generic drugs, with the aim of ensuring stable supply and reducing costs. Our manufacturing division also worked to adjust sales prices to address higher costs and difficulties in procuring raw materials caused by rising crude oil prices and China’s environmental regulations. As a result, existing raw materials for generic drug manufacturers remained weak, but sales of new raw materials for gastrointestinal drugs and anticoagulants increased significantly and remained firm.」

「In the pharmaceutical raw materials field, amid such negative factors as slowing growth in the volume share of generic drugs and surging crude oil and imported raw material prices, we focused on proposing and expanding sales of high-quality, low-cost intermediates and pharmaceutical raw materials to new drug and generic drug manufacturers. We also worked to reduce purchasing costs through multiple sourcing of raw materials, improve profitability through productivity improvements and sales price adjustments, and prepare to establish an import structure for highly potent pharmaceutical raw materials and overseas finished drug products. As a result, sales of raw materials for antipyretic analgesics, vitamins and vasoconstrictors, mainly for the US market, grew, and sales associated with the new adoption of intermediates by new drug manufacturers increased, while sales of raw materials to generic drug manufacturers remained weak.」

「Under these conditions, in the pharmaceutical raw materials field, we focused on expanding sales of high-quality, low-cost intermediates and pharmaceutical raw materials based on stable supply, while making proposals for intermediates specialized for new drug manufacturers and imported solvents. As a result, sales associated with the new adoption of intermediates by new drug manufacturers increased, but sales of raw materials to generic drug manufacturers remained weak.」

「In the pharmaceutical raw materials field, we focused on developing new overseas suppliers and expanding sales of intermediates and pharmaceutical raw materials based on high quality, low prices and stable supply. As a result, sales of pharmaceutical raw materials to generic drug manufacturers remained weak, but sales to new drug manufacturers grew as new intermediates were adopted and existing pharmaceutical raw materials were switched. Sales of vasoconstrictor raw materials, mainly for the US market, also increased.」

「In the pharmaceutical raw materials field, we actively expanded sales of existing and newly developed raw materials based on high quality, competitive pricing and stable supply, while focusing on proposals for new pharmaceutical intermediates. As a result, sales of pharmaceutical raw materials to generic drug manufacturers remained somewhat weak, but adoption of pharmaceutical intermediates by new drug manufacturers and higher sales of vasoconstrictor raw materials, mainly for the US market, kept overall performance flat.」

「In the pharmaceutical raw materials field, we proposed raw materials combining high quality, low cost and stable supply, as well as proposals to switch intermediates for existing drugs and proposals for drug discovery intermediates to new drug manufacturers. As a result, sales of raw materials related to newly developed antihypertensive drugs and other products increased, and inquiries for intermediate projects also rose. Sales also remained firm, supported by higher demand for generic pharmaceutical raw materials for synthetic antibacterial agents, existing raw materials and intermediates for new drugs following manufacturing problems at competing manufacturers.」

「In the pharmaceutical raw materials field, we advanced proposals to switch existing generic drug raw materials and proposals for intermediates to pharmaceutical raw material manufacturers. We also pursued proposals for drug discovery intermediates and contract manufacturing opportunities with new drug manufacturers, as well as proposals for new raw materials associated with the renewal of vitamin products and cold remedies for OTC drug manufacturers. As a result, in addition to higher sales from contract manufacturing of raw materials for newly developed drugs and clinical trial drugs, raw materials for generic and OTC drugs also remained firm.」

「Although deliveries of new pharmaceutical raw materials, including development products for generic drug manufacturers, increased, supply and demand for pharmaceutical raw materials supplied to existing customers remained flat. Raw materials for over-the-counter drugs also remained firm in Japan and overseas.」

「As a result, sales of existing pharmaceutical ingredients remained strong, while the adoption of new generic pharmaceutical ingredients for generic drug manufacturers and new intermediates for pharmaceutical ingredient manufacturers was decided, leading to substantial sales growth.」

「In the pharmaceutical ingredients field, the Group actively pursued sales expansion of generic pharmaceutical ingredients to existing and new customers, supported by government measures to promote generic drug use, while also focusing on exports to Europe, North America and Asia. As a result, sales of new ingredients for prescription and over-the-counter drugs grew substantially. Operating profit also increased substantially, helped by lower manufacturing costs, the adoption of new high-margin ingredients, and reductions in selling, general and administrative expenses such as logistics costs.」

「In the pharmaceutical ingredients field, the Group actively pursued sales expansion of generic pharmaceutical ingredients to existing and new customers, capitalizing on opportunities presented by market expansion and measures to ensure stable supplies of generic drugs. It also proposed low-cost ingredients and intermediates for established products to new-drug manufacturers, and new ingredients associated with vitamin product renewals to manufacturers of over-the-counter drugs.」